§ Mrs. Helen JacksonTo ask the Secretary of State for Health in which health authorities trials were conducted on the effectiveness of the drug beta interferon for sufferers of multiple sclerosis; on how many patients; and over what period. [30313]
§ Mr. MaloneSuch information is confidential. Section 118 of the Medicines Act 1968 precludes the disclosure of confidential information received in pursuance of the Act.
§ Mrs. JacksonTo ask the Secretary of State for Health (1) if he will list those authorities which have(a) agreed and (b) refused to prescribe beta interferon to MS sufferers who are suitably fit to receive it; [30314]
(2) what guidelines have been issued to health authorities regarding the prescription of the drug beta interferon to MS sufferers. [30315]
§ Mr. MaloneExecutive letter (95)/97 issued to health authorities in November 1995 suggested that, where it is clinically appropriate to prescribe beta-interferon to treat multiple sclerosis, it should be prescribed by hospital neurologists. The guidance was accompanied by clinical advice from the Standing Medical Advisory Committee. Decisions about prescribing in individual cases are a matter for clinical judgment.